[go: up one dir, main page]

FI971784A - Apolipoproteiini B-synteesin estäjiä - Google Patents

Apolipoproteiini B-synteesin estäjiä Download PDF

Info

Publication number
FI971784A
FI971784A FI971784A FI971784A FI971784A FI 971784 A FI971784 A FI 971784A FI 971784 A FI971784 A FI 971784A FI 971784 A FI971784 A FI 971784A FI 971784 A FI971784 A FI 971784A
Authority
FI
Finland
Prior art keywords
apolipoprotein
inhibitors
synthesis
Prior art date
Application number
FI971784A
Other languages
English (en)
Swedish (sv)
Other versions
FI119548B (fi
FI971784A0 (fi
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Robert Jozef Maria Hendrickx
Der Eycken Luc Alfons Leo Van
Chaffoy De Courcelles Didie De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,304 external-priority patent/US5521186A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI971784A publication Critical patent/FI971784A/fi
Publication of FI971784A0 publication Critical patent/FI971784A0/fi
Application granted granted Critical
Publication of FI119548B publication Critical patent/FI119548B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI971784A 1994-10-27 1997-04-25 Apolipoproteiini B-synteesin estäjiä FI119548B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP94203120 1994-10-27
EP94203120 1994-10-27
US08/455,304 US5521186A (en) 1994-10-27 1995-05-31 Apolipoprotein-β synthesis inhibitors
US45530495 1995-05-31
PCT/EP1995/004111 WO1996013499A1 (en) 1994-10-27 1995-10-19 Apolipoprotein-b synthesis inhibitors
EP9504111 1995-10-19

Publications (3)

Publication Number Publication Date
FI971784A true FI971784A (fi) 1997-04-25
FI971784A0 FI971784A0 (fi) 1997-04-25
FI119548B FI119548B (fi) 2008-12-31

Family

ID=26136684

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971784A FI119548B (fi) 1994-10-27 1997-04-25 Apolipoproteiini B-synteesin estäjiä

Country Status (30)

Country Link
US (1) US5929075A (fi)
EP (1) EP0788496B1 (fi)
JP (1) JP3025907B2 (fi)
KR (1) KR100227231B1 (fi)
CN (1) CN1068000C (fi)
AP (1) AP779A (fi)
AT (1) ATE198889T1 (fi)
AU (1) AU697744C (fi)
BG (1) BG63694B1 (fi)
BR (1) BR9509436A (fi)
CA (1) CA2203274C (fi)
CY (1) CY2256B1 (fi)
CZ (1) CZ286476B6 (fi)
DE (3) DE122007000005I2 (fi)
DK (1) DK0788496T3 (fi)
ES (1) ES2155535T3 (fi)
FI (1) FI119548B (fi)
GR (1) GR3035519T3 (fi)
HR (1) HRP950532B1 (fi)
HU (1) HU219862B (fi)
IL (1) IL115771A (fi)
LU (1) LU91306I2 (fi)
NO (1) NO311937B1 (fi)
NZ (1) NZ295353A (fi)
OA (1) OA10479A (fi)
PT (1) PT788496E (fi)
RO (1) RO118715B1 (fi)
SK (1) SK281908B6 (fi)
TR (1) TR199501295A2 (fi)
WO (1) WO1996013499A1 (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU746890B2 (en) * 1997-11-03 2002-05-02 Janssen Pharmaceutica N.V. Compositions of lipid lowering agents
EE200000796A (et) * 1998-04-27 2002-06-17 Janssen Pharmaceutica N.V. Ravimkuulike, selle valmistamismeetod ja farmatseutiline doseerimisvorm, ravimkuulikeste kasutaminefarmatseutilise doseerimisvormi valmistamiseks ning farmatseutiline pakend
CA2355822A1 (en) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. S-oxide lipid lowering compounds
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US20050132022A1 (en) * 2003-12-12 2005-06-16 International Business Machines Corporation Computer system with LAN-based I/O
AU2005205933B2 (en) * 2004-01-21 2010-02-18 Elanco Animal Health Ireland Limited Mitratapide oral solution
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
CA2562015A1 (en) * 2004-04-09 2005-10-20 Janssen Pharmaceutica Nv Intermittent dosing regimens of apob secretion/mtp inhibitors for overweith and obese subjects
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
DK1989196T3 (da) * 2006-02-23 2013-04-15 Pfizer Ltd Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008059335A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US8765979B2 (en) 2007-05-25 2014-07-01 Janssen Pharmaceutica Synthesis of (2S-cis)-2-(bromomethyl)-2-(4-chlorophenyl)-1,3 dioxolane-4-methanol methanesulfonate(ester)
JP5530438B2 (ja) * 2008-08-06 2014-06-25 ファイザー・リミテッド Mc4作動薬としてのジアゼピンおよびジアゾカン化合物
WO2011144653A1 (en) * 2010-05-19 2011-11-24 Sandoz Ag Process for the preparation of chiral triazolones
CN112074505B (zh) 2018-03-08 2024-04-05 因赛特公司 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4313953A (en) * 1978-06-23 1982-02-02 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
AU6359594A (en) * 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
EP0788496A1 (en) 1997-08-13
EP0788496B1 (en) 2001-01-24
NO971895D0 (no) 1997-04-24
DE69519995T2 (de) 2001-08-23
CY2256B1 (en) 2003-07-04
CA2203274C (en) 2002-02-19
SK281908B6 (sk) 2001-09-11
CN1068000C (zh) 2001-07-04
NO971895L (no) 1997-04-24
FI119548B (fi) 2008-12-31
CA2203274A1 (en) 1996-05-09
ATE198889T1 (de) 2001-02-15
LU91306I2 (fr) 2007-03-19
DE122007000005I1 (de) 2007-04-26
NO311937B1 (no) 2002-02-18
US5929075A (en) 1999-07-27
WO1996013499A1 (en) 1996-05-09
HU219862B (hu) 2001-08-28
AU697744C (en) 2002-08-22
IL115771A0 (en) 1996-01-19
IL115771A (en) 2000-02-29
BG101402A (en) 1997-10-31
HRP950532B1 (en) 2001-06-30
CZ286476B6 (en) 2000-04-12
JP3025907B2 (ja) 2000-03-27
AP9700968A0 (en) 1997-04-30
DK0788496T3 (da) 2001-06-18
HUT77360A (hu) 1998-03-30
CN1161695A (zh) 1997-10-08
RO118715B1 (ro) 2003-09-30
NZ295353A (en) 1998-08-26
TR199501295A2 (tr) 1996-06-21
AU697744B2 (en) 1998-10-15
AP779A (en) 1999-11-03
BG63694B1 (bg) 2002-09-30
DE122007000005I2 (de) 2008-04-24
SK50797A3 (en) 1998-04-08
JPH09511759A (ja) 1997-11-25
KR100227231B1 (ko) 1999-11-01
ES2155535T3 (es) 2001-05-16
GR3035519T3 (en) 2001-06-29
BR9509436A (pt) 1998-01-06
DE69519995D1 (en) 2001-03-01
MX9703074A (es) 1997-07-31
CZ119897A3 (cs) 1998-03-18
AU3868095A (en) 1996-05-23
PT788496E (pt) 2001-07-31
OA10479A (en) 2002-04-09
FI971784A0 (fi) 1997-04-25
HRP950532A2 (en) 1997-08-31

Similar Documents

Publication Publication Date Title
FI971784A (fi) Apolipoproteiini B-synteesin estäjiä
FI963597A (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
LV11178A (lv) 3-Ú4-(2-aminoetoksi) benzoil¾-2-aril-6-hidroksibenzoÚb¾tiofenu sintezes panemiens
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
DE69608448D1 (de) Reduktion des biobewuchses
IS4771A (is) Interlevkín-1ß umbreytiensím tálmar
EE9700093A (et) Apolipoproteiin-B sünteesi inhiibitorid
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
ATE230275T1 (de) Angiogense-inhibitor
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
ID24270A (id) Penghilang sumbatan keratotik
DE69632435D1 (de) Inhibitor des Hepatozytwachstumsfaktoraktivators
NO990832D0 (no) Syntese av bisendolylmalimider
ID23437A (id) Penghilang sumbatan keratotik
IT1293320B1 (it) Miscela di stabilizzanti
DE69631500D1 (de) Inhibitor des Hepatozytwachstumsfaktoraktivators
BR9610514A (pt) Inibidores cicloantihelmínticos
FI963743A0 (fi) Reniini-inhibiittorien prototyyppien synteesi
CY2007006I1 (el) Αναστολεις συνθεσης απολιποπρωτεινης-β
KR950024188U (ko) 갈치주낚용 도래의 고정구
ID17328A (id) Pemurnian epsilon-kaprolaktam
IS4339A (is) Hömlun ljóssundurliðunar á 3-setnum-2-oxindólum
KR970011853U (ko) 새로운 형태의 메리야스

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Free format text: SPC C20090011

Spc suppl protection certif: C20090011

PC Transfer of assignment of patent

Owner name: ELANCO ANIMAL HEALTH IRELAND LIMITED

Free format text: ELANCO ANIMAL HEALTH IRELAND LIMITED

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 358

Extension date: 20201019

MM Patent lapsed